

AXIM BIOTECH TO PRESENT AT 6TH ANNUAL SEETHRUEQUITY MICROCAP INVESTOR CONFERENCE IN NEW YORK CITY

NEW YORK – June 1, 2017 – [AXIM® Biotechnologies, Inc.](#) (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that George Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM, will present at the SeeThruEquity Microcap Investor Conference in New York City on June 1, 2017 at 11:30am ET. Management will also be holding 1x1 meetings with investors at the Conference.

SeeThruEquities hosts investor conferences for publicly traded companies with market capitalizations less than \$1 billion to connect potential investors and researchers with top US small-midcap companies.

AXIM's presentation will be available at the corporate website.

###

About AXIM®

AXIM® Biotechnologies, Inc. ([AXIM](#)) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit [AXIMBiotech.com](#).

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than \$1 billion. SeeThruEquity is approved to contribute

its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City. For more information visit www.seethruequity.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact

Andrew Hard

Chief Executive Officer

CMW Media

andrew.hard@cmwmedia.com

P. +1888 829-0070

www.cmwmedia.com

Investor Relations Contact

Shiwei Yin, Grayling

Shiwei.Yin@grayling.com

P. +1646 284-9474

Lucia Domville, Grayling

lucia.domville@grayling.com

P. +1646 284-9416

Corporate Contact Info

North American Address:

18 East 50th Street, 5 Floor

New York, NY 10022

+1 844 294 6246

European Address:

Boelewerf 32, Unit 3

2987 VD Ridderkerk, The Netherlands

+31 10 8209 227